Endpoints News first reported Prasad's departure.
His exit comes after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics' gene therapy, Elevidys.
"Unprecedentedly, there were multiple press leaks from the FDA, negatively impacting (its) credibility," said BMO Capital Markets analyst, Koustas Billouri.
During Prasad's short stint, the U.S. FDA limited the use of COVID-19 vaccines and declined to approve therapies from Replimmune and Capricor Therapeutics.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.